Marshall Stoller, MD
Dr. Marshall L. Stoller is medical director of the Urinary Stone Center at UCSF Medical Center that provides care for urinary stone disease including minimally invasive techniques or techniques requiring only small incisions such as endourology and laparoscopy. Stoller has helped spearhead a comprehensive program in the management of urinary stone disease, utilizing and testing a variety of lithotriptors, a non-invasive device that pulverizes urinary stones. Stoller is certified by the American Board of Urology. He has received many awards, including grand prize in the annual Lapides Essay Contest in Urodynamic and Neurourology Research.
Stoller graduated from the University of California at Berkeley in 1976 and went to medical school at Baylor College of Medicine in Houston, Texas. After medical school, he returned to the Bay Area, where he was a general surgical intern and resident and a urology resident at the University of California, San Francisco from 1981 to 1985. The following year, he became a clinical instructor and research fellow at the University of New South Wales at Prince Henry and Prince of Wales Hospitals in Sydney, Australia. Stoller returned to UCSF as chief resident in urology and then joined the medical staff. He is a professor in residence in urology and has received the Distinction in Teaching Award from the Academic Senate at UCSF.
For more information about his research, please visit Stoller’s lab website at http://stollerlab.ucsf.edu.
Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.
The urology research laboratory at Beaumont health is dedicated to translating basic research into clinical applications that will help patients with Interstitial Cystitis (IC), Radiation Cystitis (RC), or Underactive Bladder (UAB). These conditions are difficult to understand and treat, yet majorly impact the lives of millions of patients and their families. The Beaumont team seeks to close the gap in both understanding and treating these conditions. This would not be possible without the engagement of patients in research and the generosity of the Taubman Family (IC Research) and Aikens Family (UAB Research).
The Taubman Interstitial Cystitis Research Program
In 2010, the Taubman Family generously donated $500,000 to Beaumont Health System to support IC research. Utilizing the philanthropic gift, we have been able to establish a dedicated IC lab and recruited Dr. Lamb to lead molecular biology research. Beaumont Department of Urology, chaired by Dr. Kenneth Peters, is a national leading medical center in IC care and research.
Laura E. Lamb, PhD, is an assistant professor at Oakland University William Beaumont School of Medicine and Research Scientist of the Neurology Program at Beaumont Health’s Research Institute. Dr. Lamb received her doctorate in Cell and Molecular Biology at Michigan State University and completed her doctoral research at Van Andel Institute. She completed her postdoctoral fellowship in Developmental Biology and Women’s Health at Washington University in St. Louis, where she participated in the prestigious Transdisciplinary Research in Energetics and Cancer (TREC) program.
Dr. Lamb has over a decade of experience in urology, oncology, cellular and molecular biology, and immunology with expertise in cell signaling. She has presented at national and international meetings. Dr. Lamb enjoys teaching and mentoring students at all levels as well as educating the public and policymakers about how research and science impact their lives. She has been funded by the Department of Defense, the National Institute of Health, and the Center for Women’s Infectious Disease Research.
Michael B. Chancellor, MD, (Michael.email@example.com) is board-certified by the American Board of Urology and received his medical degree from Medical College of Wisconsin in Milwaukee. Dr. Chancellor completed his internship in surgery and his residency in urology at the University of Michigan in Ann Arbor. He subsequently completed his fellowship in neurourology and female urology at Columbia University and College of Physicians and Surgeons in New York. Dr. Chancellor is a world-renowned author and speaker, having been invited to present more than 650 papers at national and international meetings. He has appeared on CNN, in the pages of The Wall Street Journal, and in numerous television and radio interviews. Dr. Chancellor has written over 550 peer-reviewed articles and book chapters in journals including The Journal of Urology, Urology, Gene Therapy, and Lancet. He has also written 11 books and serves on the editorial board of 12 scientific journals.
A prolific author and researcher, Dr. Chancellor has gained national and international recognition in the areas of stem cell and tissue engineering as well as drug discovery. He was the first urologist to use botulinum toxin to treat lower urinary tract dysfunction. His inventions founded Cook MyoSite, Inc., which is now conducting multicenter North American trials using adult autologous muscle-derived stem cells to treat stress urinary incontinence. Dr. Chancellor also founded Lipella Pharmaceuticals, Inc., a biopharmaceutical company focusing on localized therapy and advance drug delivery. Dr. Chancellor has received a number of prestigious awards, including the Paul Zimskind Award from the Society of Urodynamics and Female Urology, Grand Prize in the International Jack Lapides Essay Contest, and the Pfizer-American Urological Association Visiting Professorship Award. He has been recognized as Innovator of the Year by Pittsburgh magazine, listed in Castle Connolly’s America’s Top Doctors, and named one of America’s Top Doctors by Hour Detroit magazine and by U.S. News & World Report. Dr. Chancellor has received funding from the National Institutes of Health for over a decade and has trained many of today’s experts in urology.
The Power of Partnership with the ICA and Crowdsourcing
In order to discover and validate any potential biomarker, a large number of samples from both IC patients and healthy controls are needed. This would have taken many years and millions of dollars to do even with multiple collection sites. Now, using a preservative that allows urine to be collected and shipped at ambient temperature without loss of important biological characteristics, we can, for the first time, ask people to participate in IC research from the comfort of their home. The ICA is uniquely posed to help us in this endeavor through its extensive network of people who have IC and/or care about improving the health and life for those with IC. Together, we can develop the world’s first non-invasive urine test for diagnosing IC.
Revised Tuesday, October 27th, 2015